🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We recently presented real-world data at #NANOS2025, highlighting the complexity of TED symptoms, patient journey, and management. Our findings emphasize the need for therapies that holistically address TED symptoms and improve care access. Learn more: bit.ly/427wQ90

Thanks to ASPC for raising awareness of the link between inflammation and cardiovascular disease, including the key role of IL-6. Measuring hs-CRP can help assess cardiovascular risk and guide treatment decisions. Learn more: bit.ly/3XZy03e

Thanks to Yasmeen Rahimi and Piper Sandler for the chance to reflect on ACC. Tourmaline’s Sandeep Kulkarni and Emil deGoma discussed IL-6’s role in CVD and the growing support for the therapeutic potential of IL-6 inhibition. Learn more: bit.ly/3G2bBwj

Appreciated the chance to join Truist Tru-Talks with Dr. Marc Bonaca to discuss the CVD treatment landscape, targeting inflammation, key takeaways from ACC, and the evolving vision for CVD care. Learn more: bit.ly/4dRQiZk

Appreciated the chance to join @Truist_Securities Tru-Talks with Dr. Marc Bonaca to discuss the CVD treatment landscape, targeting inflammation, key takeaways from ACC, and the evolving vision for CVD care. Learn more: bit.ly/4dRQiZk

Dr. Seth Baum highlights the growing consensus: targeting IL-6 may be key to reducing residual risk in ASCVD. Tourmaline is seeking to develop a differentiated approach to address inflammation in high-risk patients. Learn more: bit.ly/4jklww5

Enjoyed connecting at the Piper Sandler Spring Biopharma Symposium. With key milestones ahead, we’re excited by the momentum behind IL-6 and the potential to reshape cardiovascular care with targeted anti-inflammatory therapies. Learn more: bit.ly/4dRQiZk

Thanks to Josh Schimmer (josh schimmer) and the Cantor team for spotlighting AAA. We’re excited about IL-6 inhibition’s potential in this underserved space and the possibilities ahead for pacibekitug in CVD. Learn more: bit.ly/3G2bBwj

Our team joined Jefferies' Roger Song to discuss Tourmaline’s development strategy for pacibekitug across ASCVD, AAA, and TED. With a strong evidentiary foundation, we’re advancing efforts designed to address significant unmet medical needs.

New in Frontiers in Ophthalmology: Tourmaline team members co-authored a review on IL-6 in TED, highlighting its role in the pathogenesis of the disease and its potential as a biomarker and therapeutic target. Read more: bit.ly/427wQ90

We just announced Q1 2025 financial results and recent business highlights. We look forward to the expected reporting of topline data from our Phase 2 TRANQUILITY trial in patients with elevated hs-CRP and CKD in Q2 2025. Read more here: bit.ly/431Vuqo

What if a simple blood test could reveal hidden cardiovascular risk? Dr. Paul Ridker, who serves on our CV SAB, makes the case for universal hs-CRP screening in this powerful talk via ASPC—inflammation matters. Watch now: bit.ly/44t6j79

We’re proud to feature Shana Berti as the first standout in our Employee Spotlight Series. As Sr. Manager of Supply Chain, her work touches nearly every part of the company, playing a key role in our work towards improving patient outcomes. #TeamTourmaline

Tourmaline to present topline results from the ongoing Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease on May 20, 2025 at 8:30 am ET To register for this event: bit.ly/4kvUC4y

Even with current therapies, people w/ ASCVD face a 30% risk of major CV events over 10 yrs (a meta-analysis by Kaasenbrood et al). Residual inflammatory risk is a key driver. We’re proud to support @ASPC’s efforts in spotlighting this issue. Learn more: bit.ly/3FKnZ4h

Sandeep Kulkarni joined @TyGluckman for a @CantorFitzgerald Cardio Month webinar to discuss the link between inflammation & ASCVD + the potential of IL-6 inhibition. Learn more about our science & the positive topline results from the P2 TRANQUILITY trial: bit.ly/3ZTbzOq

Tourmaline CEO, Sandeep Kulkarni and CFO, Ryan Robinson participated in Leerink Partners ’ I&I and Metabolism Forum to discuss IL-6’s role in disease progression and the need for continued innovation in immune and inflammatory diseases. Learn more: bit.ly/4eCUrCy

Often called a “ticking time bomb,” abdominal aortic aneurysm (AAA) is a silent but serious threat. If undetected, a AAA can grow unnoticed until it ruptures- an event that is frequently fatal. Despite this, treatment options remain limited. Learn more bit.ly/453FLbp